A thermally activated delayed fluorescent molecular material, a method for synthesizing the same, and an organic electroluminescent device are provided. The thermally activated delayed fluorescent molecular material includes an electron donor and an electron acceptor containing an indenyl group. A phenyl group in diphenylamine or triphenylamine in a donor molecule is replaced with an indenyl group, so that the electron-donating ability of the donor is increased, and the non-radiative transition rate is effectively suppressed, thereby increasing the photoluminescence quantum yield (PLQY) of the molecule. Further, the torsion angle between the electron donor and the electron acceptor is also increased, while the electron cloud overlap between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) is reduced, thereby obtaining a smaller ΔE.sub.ST value.

A thermally activated delayed fluorescent molecular material, a method for synthesizing the same, and an organic electroluminescent device are provided. The thermally activated delayed fluorescent molecular material includes an electron donor and an electron acceptor containing an indenyl group. A phenyl group in diphenylamine or triphenylamine in a donor molecule is replaced with an indenyl group, so that the electron-donating ability of the donor is increased, and the non-radiative transition rate is effectively suppressed, thereby increasing the photoluminescence quantum yield (PLQY) of the molecule. Further, the torsion angle between the electron donor and the electron acceptor is also increased, while the electron cloud overlap between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) is reduced, thereby obtaining a smaller ΔE.sub.ST value.

Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 (CTPS 1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 129 to page 302; examples; biological examples 1 and 2; tables 1-17). Specific examples are e.g.: N-(4-(5-Chloropyridin-3-yl)phenyl)-2-(2-(cyclopropane-sulfonamido) pyrimidin-4-yl)butanamide (Formula P1) or 1-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)phenyl)cyclopentanecarboxamide (Formula P2).

##STR00001##

Compounds of Formula I and Formula II:

##STR00001##

pharmaceutical compositions containing them, and use of the compounds as active ingredients to treat infection with alphavirus.

The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

An organic electroluminescence device includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region, wherein the hole transport region includes a polycyclic compound represented by Formula 5 or Formula 6, thereby showing high emission efficiency.

An organic electroluminescence device includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region, wherein the hole transport region includes a polycyclic compound represented by Formula 5 or Formula 6, thereby showing high emission efficiency.

Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.

##STR00001##